[{"id":"a334d333-a3ba-49e5-a0c5-4e85464ed3d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470489","created_at":"2026-03-28T01:44:21.005Z","updated_at":"2026-03-28T01:44:21.005Z","phase":"Phase 2","brief_title":"A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial","source_id_and_acronym":"NCT07470489","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/30/2026","start_date":" 09/30/2026","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2026-03-13"},{"id":"0ad91159-5e74-4841-9bb6-f71f53c01cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07181720","created_at":"2025-09-20T07:06:00.818Z","updated_at":"2025-09-20T07:06:00.818Z","phase":"Phase 1","brief_title":"Safety and Efficacy of CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors: A Clinical Trial","source_id_and_acronym":"NCT07181720","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD70 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/12/2025","start_date":" 09/12/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-09-18"},{"id":"b0935c07-a451-47fa-8f96-112ab5dc4cae","acronym":"TATC","url":"https://clinicaltrials.gov/study/NCT07138261","created_at":"2025-08-30T14:02:24.019Z","updated_at":"2025-08-30T14:02:24.019Z","phase":"","brief_title":"Taiwanese Anaplastic Thyroid Cancer Registry","source_id_and_acronym":"NCT07138261 - TATC","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/30/2035","primary_completion_date":" 12/30/2035","study_txt":" Completion: 12/30/2035","study_completion_date":" 12/30/2035","last_update_posted":"2025-08-22"},{"id":"2006a2aa-ecdd-452a-aec0-f278d895e6f1","acronym":"OTELLO","url":"https://clinicaltrials.gov/study/NCT07064369","created_at":"2025-07-19T14:09:59.980Z","updated_at":"2025-07-19T14:09:59.980Z","phase":"","brief_title":"Observational Study on Thyroid Tumors and EvaLuation of the roLe of New pOntential Predictive/Prognostic Factors","source_id_and_acronym":"NCT07064369 - OTELLO","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 100","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-07-14"},{"id":"5d7c4997-a66f-432c-ad34-60966069c8bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07054229","created_at":"2025-07-12T13:57:43.569Z","updated_at":"2025-07-12T13:57:43.569Z","phase":"","brief_title":"Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study","source_id_and_acronym":"NCT07054229","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 480","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-07-08"},{"id":"f19011bc-a0f1-46bf-8979-e38379c2fbd2","acronym":"NEO-COMBATXL","url":"https://clinicaltrials.gov/study/NCT06902376","created_at":"2025-06-07T14:40:06.805Z","updated_at":"2025-06-07T14:40:06.805Z","phase":"Phase 1","brief_title":"XL092 and Cemiplimab in BRAF WT Thyroid Cancer","source_id_and_acronym":"NCT06902376 - NEO-COMBATXL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/03/2025","start_date":" 06/03/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-06-04"},{"id":"71e55178-c77a-4646-b887-97974cb14980","acronym":"","url":"https://clinicaltrials.gov/study/NCT06969768","created_at":"2025-07-19T14:06:25.454Z","updated_at":"2025-07-19T14:06:25.454Z","phase":"","brief_title":"Proteogenomics for Follicular Cell-derived Thyroid Cancer: Development of a Classification and Prognosis Prediction Model","source_id_and_acronym":"NCT06969768","lead_sponsor":"Seoul National University Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Completed","enrollment":" Enrollment 275","initiation":"Initiation: 02/21/2018","start_date":" 02/21/2018","primary_txt":" Primary completion: 02/21/2021","primary_completion_date":" 02/21/2021","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2025-05-14"},{"id":"e1921994-65db-438f-afac-ccc5915b012d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06901908","created_at":"2025-07-19T14:06:19.418Z","updated_at":"2025-07-19T14:06:19.418Z","phase":"","brief_title":"Role of Cytomorphometry and BRAFV600E Immunocytochemistry With a Cytologic Diagnosis \"Suspicious for Papillary Thyroid Carcinoma\"","source_id_and_acronym":"NCT06901908","lead_sponsor":"Assiut University","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-04-03"},{"id":"b44521d2-5829-4bf3-b6c2-ad08cfcaf642","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863805","created_at":"2025-07-19T14:06:15.287Z","updated_at":"2025-07-19T14:06:15.287Z","phase":"","brief_title":"Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas","source_id_and_acronym":"NCT06863805","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" BRAF • ALK • RET • RAS • NTRK","pipe":" | ","alterations":" RAS mutation • RET mutation","tags":["BRAF • ALK • RET • RAS • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • RET mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-03-07"},{"id":"3174eb09-547d-4053-9bb7-a8326b4fcbac","acronym":"","url":"https://clinicaltrials.gov/study/NCT03841617","created_at":"2021-07-05T17:20:24.574Z","updated_at":"2025-02-25T12:27:07.917Z","phase":"Phase 2","brief_title":"The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03841617","lead_sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","biomarkers":" BRAF • TG","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/29/2019","start_date":" 07/29/2019","primary_txt":" Primary completion: 02/01/2030","primary_completion_date":" 02/01/2030","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2025-02-24"},{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"58d26922-dd62-4243-8588-89fbcbf5d940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02152995","created_at":"2021-03-24T14:59:26.184Z","updated_at":"2025-02-25T12:26:08.615Z","phase":"Phase 2","brief_title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02152995","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • NRAS • HRAS • EGF","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61","tags":["HER-2 • KRAS • BRAF • NRAS • HRAS • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/14/2014","start_date":" 08/14/2014","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 01/25/2026","study_completion_date":" 01/25/2026","last_update_posted":"2025-02-24"},{"id":"48df85e5-b786-45f4-a391-eab53ca69d44","acronym":"AMPLIFY","url":"https://clinicaltrials.gov/study/NCT04000880","created_at":"2024-02-21T19:24:47.029Z","updated_at":"2025-02-25T13:48:43.597Z","phase":"","brief_title":"Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health","source_id_and_acronym":"NCT04000880 - AMPLIFY","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" IL6 • TNFA • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CRP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 603","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-21"},{"id":"81796e46-09bd-4096-9e4d-f21de4f6ddd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01247597","created_at":"2021-01-18T05:01:29.106Z","updated_at":"2025-02-25T13:38:59.492Z","phase":"","brief_title":"DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study","source_id_and_acronym":"NCT01247597","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" DICER1","pipe":"","alterations":" ","tags":["DICER1"],"overall_status":"Recruiting","enrollment":" Enrollment 1500","initiation":"Initiation: 02/13/2011","start_date":" 02/13/2011","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"e4ad6b8c-e058-4c8c-a933-f8fdb32f0b5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06270082","created_at":"2024-02-21T20:26:46.390Z","updated_at":"2025-02-25T14:42:43.633Z","phase":"Phase 1","brief_title":"Study of IK-595 in RAS- or RAF-altered Advanced Tumors","source_id_and_acronym":"NCT06270082","lead_sponsor":"Ikena Oncology","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-14"},{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"6a7e9990-a739-46e3-a955-92f98bf580c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04927416","created_at":"2021-06-16T18:52:38.190Z","updated_at":"2025-02-25T15:35:06.877Z","phase":"Phase 2","brief_title":"The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer","source_id_and_acronym":"NCT04927416","lead_sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 overexpression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 overexpression"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 11/30/2030","primary_completion_date":" 11/30/2030","study_txt":" Completion: 11/30/2030","study_completion_date":" 11/30/2030","last_update_posted":"2025-02-10"},{"id":"74af1789-bdc4-49be-8227-be00ab7f39a0","acronym":"PALOMA","url":"https://clinicaltrials.gov/study/NCT04606381","created_at":"2021-01-19T20:31:31.743Z","updated_at":"2025-02-25T15:34:47.299Z","phase":"Phase 1","brief_title":"A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies","source_id_and_acronym":"NCT04606381 - PALOMA","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" MET","pipe":" | ","alterations":" EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 07/11/2024","primary_completion_date":" 07/11/2024","study_txt":" Completion: 10/21/2025","study_completion_date":" 10/21/2025","last_update_posted":"2025-02-10"},{"id":"f5887694-2af2-431c-9929-09e65d372e4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05355701","created_at":"2022-05-02T12:57:00.809Z","updated_at":"2025-02-25T15:35:37.767Z","phase":"Phase 1","brief_title":"A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","source_id_and_acronym":"NCT05355701","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Mektovi (binimetinib) • claturafenib (PF-07799933)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 07/05/2022","start_date":" 07/05/2022","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 03/26/2028","study_completion_date":" 03/26/2028","last_update_posted":"2025-02-10"},{"id":"11565097-46a7-40c4-bd2e-84aac455986c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01638533","created_at":"2021-01-18T07:02:41.766Z","updated_at":"2025-02-25T14:33:33.086Z","phase":"Phase 1","brief_title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","source_id_and_acronym":"NCT01638533","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • AFP","pipe":"","alterations":" ","tags":["ER • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/03/2012","start_date":" 08/03/2012","primary_txt":" Primary completion: 11/29/2018","primary_completion_date":" 11/29/2018","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2025-02-07"},{"id":"1c396f9f-301a-4705-afde-65c99cd26512","acronym":"LIBRETTO-321","url":"https://clinicaltrials.gov/study/NCT04280081","created_at":"2021-01-18T20:46:57.085Z","updated_at":"2025-02-25T16:32:06.121Z","phase":"Phase 2","brief_title":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation","source_id_and_acronym":"NCT04280081 - LIBRETTO-321","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 03/25/2021","primary_completion_date":" 03/25/2021","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"876ce078-02f8-4b29-96fc-e46147d9c92f","acronym":"PYX-201-101","url":"https://clinicaltrials.gov/study/NCT05720117","created_at":"2023-09-21T18:11:07.087Z","updated_at":"2025-02-25T16:39:39.072Z","phase":"Phase 1","brief_title":"Study of PYX-201 in Solid Tumors","source_id_and_acronym":"NCT05720117 - PYX-201-101","lead_sponsor":"Pyxis Oncology, Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e micvotabart pelidotin (PYX-201)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-06"}]